MaxCyte

MaxCyte Introduces Rapid, Automated, Scalable Flow Electroporation-based Technology for Vaccine Development

Data on the use of MaxCyte electroporation to transfect insect cells without baculovirus to be presented. March 20, 2014 MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will present data in both a scientific talk and a poster during the World Vaccine Congress on March 24-26, 2014, that demonstrates the use of flow electroporation for the rapid and …

MaxCyte

Download MaxCyte Flow Electroporation: Vaccine Research & Development

In the run-up to the World Vaccine Congress, MaxCyte has provided us with this whitepaper on Flow Electroporation and its implications in vaccine research and development.  “MaxCyte’s proprietary flow electroporation is a universal transient transfection technology for rapid, high-quality cell transfection. Flow electroporation enables (co)transfection of a wide range of cells with DNA, RNA, siRNA, proteins, or cell lysates and …